Terbium-161 was applied with somatostatin receptor (SSTR) agonists that localize in the cytoplasm (DOTATOC) and cellular nucleus (DOTATOC-NLS) or with a SSTR antagonist that localizes at the cell membrane (DOTA-LM3). The aim was to identify the most favorable peptide/terbium-161 combination for the treatment of neuroendocrine neoplasms (NENs).

2024年3月7日 · Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms.

161Tb-DOTA-LM3: 一种SSTR2拮抗剂、电离辐射发射源药物，由Universitätsspital Basel (Universitätsspital Basel)公司最早进行研发，目前全球最高研发状态为早期临床1期，作用机制: SSTR2拮抗剂(生长抑素受体2拮抗剂),电离辐射发射源，治疗领域: 肿瘤,消化系统疾病,内分泌与代 …

Terbium-161 has been successfully used for the radiolabeling of DOTA-functionalized molecules, such as the tumor-targeted DOTA-folate conjugate [24, 25], the somatostatin receptor-specific analog DOTATOC [16, [26], [27], [28], [29]], the somatostatin analog DOTATOC-NLS, the somatostatin receptor antagonist DOTA-LM3 [28], and PSMA-617 [[29], [30 ...

2023年7月12日 · Short-ranged electrons emitted by terbium-161 are unlikely to cause radionephropathy in patients treated with radiopharmaceuticals, in which lutetium-177 is replaced by terbium-161, provided that the renal radiation dose does not exceed the safe limit of 23 Gy.

2021年4月12日 · The 161 Tb- and 177 Lu-labeled somatostatin (SST) analogues DOTATOC (agonist) and DOTA-LM3 (antagonist) were tested in vitro to demonstrate equal properties regarding distribution coefficients and cell uptake into SST receptor-positive AR42J tumor cells. The radiopeptides were further investigated in AR42J tumor-bearing nude mice using the ...

2021年10月8日 · Terbium-161 was applied with somatostatin receptor (SSTR) agonists that localize in the cytoplasm (DOTATOC) and cellular nucleus (DOTATOC-NLS) or with a SSTR antagonist that localizes at the cell membrane (DOTA-LM3). The aim was to identify the most favorable peptide/terbium-161 combination for the treatment of …

2024年3月7日 · Here, we report on the first patient (78-year-old man) with a metastatic, hormone-active (carcinoid syndrome) ileal neuroendocrine tumour (G1, Ki-67, < 3%), who received a test infusion of 1 GBq [161 Tb]Tb-DOTA-LM3 in an ongoing prospective Phase 0 study.

本届年会上，一项名为“Therapy with the somatostatin receptor antagonist DOTA-LM3 labeled with Terbium-161: Interim results of the Phase 0 Study in patients with gastroenteropancreatic neuroendocrine tumors”的研究荣获了玛丽居里奖。 欧洲核医学年会一年一度所颁发的玛丽居里奖是给本年度大会上就科学质量而言贡献度最好的研究，旨在鼓励为核医学领域做出突出成果的欧洲研究团队。 本年度的获奖研究内容是利用新兴治疗核素161Tb标记一种靶向生长抑素受体的拮 …

在分别使用 DOTATOC 或 DOTA-LM3 对小鼠进行的治疗研究中，研究了 terbium-161 与 lutetium-177 的疗效。 结果 在体外，[161Tb]Tb-DOTA-LM3 的效力是 [177Lu]Lu-DOTA-LM3 的 102 倍；然而，161Tb 标记的 DOTATOC 和 DOTATOC-NLS 对肿瘤细胞活力的抑制效果仅比 177Lu 标记的对应物高 4 到 5 倍。